Grifols Value Stock - Dividend - Research Selection
Market price: 11,16 EUR
Grifols SA Fundamental data and company key figures of the share
|Annual reports in EUR|
|Net operating cash flow||1.110.340.000|
|Free cash flow||747.779.968|
|Liabilities & Shareholders equity||15.274.800.000|
|Diluted shares outstanding||684.543.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||9.265.615.872,00 USD|
|Indices||IBEX 35,STOXX EUROPE 600,MSCI World Index|
|Raw Data Source||IFRS in Millionen EUR|
|Stock Split||2016-01-05,2.0000/1.0000; 2016-01-04,2.0000/1.0000; 2012-12-11,2.0000/1.0000|
Description of the company
Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma for therapeutic use. The Hospital division offers non-biological pharmaceutical products and medical supplies for hospital pharmacy. The Diagnostic division provides clinical analysis and laboratory testing tools to laboratories, hospitals and blood banks. The Raw materials division includes sales of intermediate biological products, as well as manufacturing services to third parties. The Company operates production facilities in Spain, the United States, Mexico and Australia, among others. It controls numerous subsidiaries.